 |
 |
hi all i did a search on ( Rinne U ) and 281 citations were found (!!) here are the first 20 ... janet ------------------------------------- 1: Teravainen H, Rinne U, Gordin A. Catechol-O-methyltransferase inhibitors in Parkinson's disease. Adv Neurol. 2001;86:311-25. Review. No abstract available. PMID: 11553991 [PubMed - indexed for MEDLINE] 2: Kuopio A, Marttila RJ, Helenius H, Rinne UK. Familial occurrence of Parkinson's disease in a community-based case-control study. Parkinsonism Relat. Disord.. 2001 Oct;7(4):297-303. PMID: 11344013 [PubMed - as supplied by publisher] 3: Ruottinen HM, Niinivirta M, Bergman J, Oikonen V, Solin O, Eskola O, Eronen E, Sonninen P, Rinne UK. Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging. Synapse. 2001 Apr;40(1):19-26. PMID: 11170218 [PubMed - indexed for MEDLINE] 4: Rinne UK. Treatment of early Parkinson's disease. Parkinsonism Relat. Disord.. 2000 Nov 1;7(1):59-62. PMID: 11008197 [PubMed - as supplied by publisher] 5: Laihinen A, Ruottinen H, Rinne JO, Haaparanta M, Bergman J, Solin O, Koskenvuo M, Marttila R, Rinne UK. Risk for Parkinson's disease: twin studies for the detection of asymptomatic subjects using [18F]6-fluorodopa PET. J Neurol. 2000 Apr;247 Suppl 2:II110-3. PMID: 10991657 [PubMed - indexed for MEDLINE] 6: Portin R, Laatu S, Revonsuo A, Rinne UK. Impairment of semantic knowledge in Parkinson disease. Arch Neurol. 2000 Sep;57(9):1338-43. PMID: 10987902 [PubMed - indexed for MEDLINE] 7: Kuopio AM, Marttila RJ, Helenius H, Toivonen M, Rinne UK. The quality of life in Parkinson's disease. Mov Disord. 2000 Mar;15(2):216-23. PMID: 10752569 [PubMed - indexed for MEDLINE] 8: Kuopio AM, Marttila RJ, Helenius H, Rinne UK. Environmental risk factors in Parkinson's disease. Mov Disord. 1999 Nov;14(6):928-39. PMID: 10584666 [PubMed - indexed for MEDLINE] 9: Rinne UK, Gordin A, Teravainen HT. COMT inhibition with entacapone in the treatment of Parkinson's disease. Adv Neurol. 1999;80:491-4. Review. No abstract available. PMID: 10410761 [PubMed - indexed for MEDLINE] 10: Rinne UK. [Combination therapy with lisuride and L-dopa in the early stages of Parkinson's disease decreases and delays the development of motor fluctuations. Long-term study over 10 years in comparison with L-dopa monotherapy] Nervenarzt. 1999 Jan;70 Suppl 1:S19-25. German. PMID: 10087526 [PubMed - indexed for MEDLINE] 11: Przuntek H, Conrad B, Dichgans J, Kraus PH, Krauseneck P, Pergande G, Rinne U, Schimrigk K, Schnitker J, Vogel HP. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol. 1999 Mar;6(2):141-50. PMID: 10053226 [PubMed - indexed for MEDLINE] 12: Kuopio AM, Marttila RJ, Helenius H, Rinne UK. Changing epidemiology of Parkinson's disease in southwestern Finland. Neurology. 1999 Jan 15;52(2):302-8. PMID: 9932948 [PubMed - indexed for MEDLINE] 13: Rinne UK, Larsen JP, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology. 1998 Nov;51(5):1309-14. PMID: 9818851 [PubMed - indexed for MEDLINE] 14: Ruottinen HM, Rinne UK. COMT inhibition in the treatment of Parkinson's disease. J Neurol. 1998 Nov;245(11 Suppl 3):P25-34. Review. PMID: 9808337 [PubMed - indexed for MEDLINE] 15: Olanow CW, Myllyla VV, Sotaniemi KA, Larsen JP, Palhagen S, Przuntek H, Heinonen EH, Kilkku O, Lammintausta R, Maki-Ikola O, Rinne UK. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis. Neurology. 1998 Sep;51(3):825-30. PMID: 9748034 [PubMed - indexed for MEDLINE] 16: Troconiz IF, Naukkarinen TH, Ruottinen HM, Rinne UK, Gordin A, Karlsson MO. Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone. Clin Pharmacol Ther. 1998 Jul;64(1):106-16. PMID: 9695725 [PubMed - indexed for MEDLINE] 17: Ruottinen HM, Rinne JO, Ruotsalainen UH, Bergman JR, Oikonen VJ, Haaparanta MT, Solin OH, Laihinen AO, Rinne UK. Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1995;10(2-3):91-106. PMID: 9620057 [PubMed - indexed for MEDLINE] 18: Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs. 1998;55 Suppl 1:23-30. PMID: 9483167 [PubMed - indexed for MEDLINE] 19: Ruottinen HM, Rinne JO, Oikonen VJ, Bergman JR, Haaparanta MT, Solin OH, Ruotsalainen UH, Rinne UK. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral COMT and MAOB: differing response inrelation to presynaptic dopaminergic dysfunction. Synapse. 1997 Dec;27(4):336-46. PMID: 9372556 [PubMed - indexed for MEDLINE] 20: Ma SY, Roytta M, Rinne JO, Collan Y, Rinne UK. Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts. J Neurol Sci. 1997 Oct 3;151(1):83-7. PMID: 9335015 [PubMed - indexed for MEDLINE] http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?SUBMIT=y janet paterson: an akinetic rigid subtype, albeit primarily perky, parky pd: 55/41/37 cd: 55/44/43 tel: 613 256 8340 email: [log in to unmask] smail: 375 Country Street, Almonte, Ontario, Canada, K0A 1A0 a new voice website: http://www.geocities.com/janet313/ ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn